Randomised, placebo‐controlled trial and meta‐analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial

Ondansetron may be beneficial in irritable bowel syndrome with diarrhoea (IBS‐D).

[1]  E. Savarino,et al.  Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome with Constipation or Diarrhea: Meta-Analysis. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  L. Marciani,et al.  Psyllium reduces inulin-induced colonic gas production in IBS: MRI and in vitro fermentation studies , 2021, Gut.

[3]  Xiaoqing Li,et al.  Depression and Structural Factors Are Associated With Symptoms in Patients of Irritable Bowel Syndrome With Diarrhea , 2020, Journal of neurogastroenterology and motility.

[4]  R. Fathi,et al.  Bimodal Release Ondansetron Improves Stool Consistency and Symptomatology in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Trial. , 2020, The American journal of gastroenterology.

[5]  P. Whorwell,et al.  Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. , 2020, Gastroenterology.

[6]  P. Whorwell,et al.  Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial , 2019, Trials.

[7]  W. Chey,et al.  Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome , 2018, Current medical research and opinion.

[8]  W. Goodman,et al.  High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions , 2018, Neuropsychopharmacology.

[9]  J. Turvill,et al.  Evaluation of the clinical and cost-effectiveness of the York Faecal Calprotectin Care Pathway , 2018, Frontline Gastroenterology.

[10]  A. Zinsmeister,et al.  Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel Syndrome–Diarrhea Without Bile Acid Malabsorption , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  C. Salisbury,et al.  Clinical workload in UK primary care: a retrospective analysis of 100 million consultations in England, 2007–14 , 2016, The Lancet.

[12]  R. Sood,et al.  Evaluation of a faecal calprotectin care pathway for use in primary care , 2016, Primary Health Care Research & Development.

[13]  T. Okumura,et al.  Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study , 2016, Journal of Gastroenterology.

[14]  L. Turner,et al.  Eluxadoline for Irritable Bowel Syndrome with Diarrhea. , 2016, The New England journal of medicine.

[15]  R. Spiller,et al.  Bowel Disorders. , 2016, Gastroenterology.

[16]  M. Hastings,et al.  A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D) , 2015, Gut.

[17]  S. Fukudo,et al.  Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  P. Whorwell,et al.  Faecal incontinence—the hidden scourge of irritable bowel syndrome: a cross-sectional study , 2014, BMJ open gastroenterology.

[19]  D. Drossman,et al.  Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients , 2013, Health and Quality of Life Outcomes.

[20]  I. Hall,et al.  A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea , 2013, Gut.

[21]  K. Garsed,et al.  Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit , 2013, Gut.

[22]  M. Hastings,et al.  The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease , 2010, Alimentary pharmacology & therapeutics.

[23]  Lin Chang,et al.  Ischemic Colitis and Complications of Constipation Associated With the Use of Alosetron Under a Risk Management Plan: Clinical Characteristics, Outcomes, and Incidences , 2010, The American Journal of Gastroenterology.

[24]  M. Camilleri,et al.  Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[25]  P. Whorwell,et al.  Effect of the NK3 receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans , 2007, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[26]  P. Moayyedi,et al.  The Short‐Form Leeds Dyspepsia Questionnaire validation study , 2007, Alimentary pharmacology & therapeutics.

[27]  R. Bolus,et al.  Characterization of the Alternating Bowel Habit Subtype in Patients with Irritable Bowel Syndrome , 2005, The American Journal of Gastroenterology.

[28]  A. Dickenson,et al.  Does a Single Intravenous Injection of the 5HT3 Receptor Antagonist Ondansetron Have an Analgesic Effect in Neuropathic Pain? A Double-Blinded, Placebo-Controlled Cross-Over Study , 2003, Anesthesia and analgesia.

[29]  P. Jhingran,et al.  Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome , 2001, American Journal of Gastroenterology.

[30]  K W Heaton,et al.  Irritable bowel syndrome in general practice: prevalence, characteristics, and referral , 2000, Gut.

[31]  M. Delvaux,et al.  Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome , 1998, Alimentary pharmacology & therapeutics.

[32]  P. Whorwell,et al.  The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress , 1997, Alimentary pharmacology & therapeutics.

[33]  M. Vatn,et al.  A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. , 1996, Scandinavian journal of gastroenterology.

[34]  M. Camilleri,et al.  Serotonergic mediation of postprandial colonic tonic and phasic responses in humans. , 1994, Gut.

[35]  M. Camilleri,et al.  Effect of a 5HT3‐antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome , 1993, Alimentary pharmacology & therapeutics.

[36]  R. Snaith,et al.  The Hospital Anxiety And Depression Scale , 2003, Health and quality of life outcomes.

[37]  A. Nielsen,et al.  Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study. , 1987, Scandinavian journal of gastroenterology. Supplement.

[38]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.